- PDS Biotechnology (PDSB, Financial) announces three clinical trial presentations at the 2025 ASCO Annual Meeting.
- Key focus on Versamune® HPV (PDS0101) for HPV-related head and neck cancers.
- Presentations to occur in Chicago from May 30 to June 3, 2025.
PDS Biotechnology Corporation (PDSB) has revealed that three abstracts featuring their investigational immunotherapy, Versamune® HPV (PDS0101), have been accepted for presentation at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The conference is scheduled to take place in Chicago, Illinois, from May 30 to June 3, 2025.
The abstracts encompass data from pivotal clinical trials evaluating the efficacy of PDS0101 in combination with pembrolizumab for treating HPV16-positive head and neck squamous cell carcinomas, as well as initial results for using PDS0101 with pembrolizumab in advanced HPV-associated oropharyngeal carcinoma.
The VERSATILE-003 Phase 3 trial, which will be one of the highlights at the meeting, compares the combination therapy of PDS0101 and pembrolizumab against pembrolizumab alone for first-line treatment. This study underscores PDSB's ongoing commitment to advancing immunotherapy solutions for cancer treatment.
The presentations are set to take place during the Head and Neck Cancer Poster Session on Monday, June 2, 2025, from 9:00 a.m. to 12:00 p.m. CDT, promising important insights into the potential clinical benefits of PDS0101.
